pharma

Is Lilly and Amylin's Byetta Better?

This AMLN pumping is just disgusting.

During the last 4 years company insiders received and cashed out huge amounts of granted options in spite of terrible sale or stock price performance.

AMLN has total disregard for it shareholders.

AMLN was burning money having huge expenses but their clinical trials looked more like Mickey Mouse trials with too few patients to be conclusive.

The last trial for LAR Byetta was a comparative trial with so few patients than it is impossible to make any definite conclusion regarding either Byetta or LAR Byetta efficacy.

Icahn Boosts Stake in Amylin to 6.5%, Seeks Additional Talks

I was AMLN's shareholders from 1998 until 2007.

AMLN's situation is very complex:
- its management is very greedy and incompetent
- Symlin is a niche drug as of now with very limited sale potential
- Byetta is their major product responsible for 90% of AMLN sale and it has a strong competition from Merck's Januvia. Byetta LAR is the most important AMLN program since Byetta competition is coming from all sides.

Finally, Byetta and Byetta LAR are partnered with LLY. This agreement is very complex and not in AMLN favor. In a case of AMLN is taken over by other company, LLY has rights to demand transferring Byetta franchise to them.

Based on my experience (IMCL investor from 1998)with ImClone where Carl is the BOD Chairman, Carl is a greenmailer and knows nothing about complexity of biotech business. If not for IMCL's partner Merck KgaA who does all Erbitux R&D, IMCL would be long ago out of business.